SCHEMBL3248351

SCHEMBL3248351

CC(=O)O[C@@H]1[C@@H](O[C@H]2[C@@H](OCc3ccccc3)[C@H](OCc3ccccc3)[C@@H](COCc3ccccc3)O[C@@H]2Sc2ccccc2)O[C@H](COCc2ccccc2)[C@@H](OCc2ccccc2)[C@@H]1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.47
PTPN1 P18031 9/20 0.46
PTPN2 P17706 3/20 0.46
PTPN11 Q06124 3/20 0.46
CDC25B P30305 6/20 0.45
PTPN6 P29350 2/20 0.43
GJB2 P29033 2/20 0.43
TACR2 P21452 2/20 0.43
SSTR1 P30872 1/20 0.42
SSTR2 P30874 1/20 0.42
SSTR4 P31391 1/20 0.42
SSTR3 P32745 1/20 0.42
SSTR5 P35346 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA4 P22748 2/20 0.41
CA5A P35218 2/20 0.41
CA7 P43166 2/20 0.41
CA5B Q9Y2D0 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10261679 0.97 PTPN1 (0.47) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL13857172 0.95 PTPN1 (0.46) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL13857171 0.94 PTPN1 (0.45) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL27426316 0.92 CA12 (0.48) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL10261481 0.92 CA12 (0.48) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL24107751 0.90 NT5E (0.55) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL13857167 0.88 NT5E (0.47) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL26273709 0.85 CA12 (0.48) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL3241246 0.85 GJB2 (0.49) NT5EPTPN1PTPN2PTPN11CDC25B
SCHEMBL8055010 0.85 NT5E (0.51) NT5EPTPN1PTPN2PTPN11CDC25B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1232167-B1 SYNTHETIC OLIGOMANNOSIDES, PREPARATION AND USES THEREOF CT HOSPITALIER REGIONAL ET UNI (FR) 2010-05-05 EP disclosed
US-20060270627-A1 Synthetic oligomannosides, preparation and uses thereof CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE (CHRU) (FR) 2006-11-30 US disclosed
US-7109182-B2 Synthetic oligomannosides, preparation and uses thereof CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE (CHRU) (FR) 2006-09-19 US disclosed
US-20030105060-A1 Synthetic oligomannosides, preparation and uses thereof CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE (CHRU) (FR) 2003-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105060-A1 Synthetic oligomannosides, preparation and uses thereof DDOST, MANBA, ALG1 NT5E 1946/4885PTPN1 1241/4885PTPN2 1234/4885
US-20060270627-A1 Synthetic oligomannosides, preparation and uses thereof DDOST, MANBA, ALG1 NT5E 1946/4885PTPN1 1241/4885PTPN2 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.